Barclays Raises Price Target on Edwards Lifesciences Following Q1 Earnings
Barclays raised its price target on Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104, maintaining an Overweight rating after the company's strong first-quarter earnings. The firm highlighted share gains in Europe and the U.S., with Q1 sales rising 16.7% year-over-year.
